IL-33 neutralization suppresses lupus disease in lupus-prone mice

Inflammation

Volumn 37, Issue 3, 2014, Pages 824-832

  Li, Pin ^a   Lin, Wei ^a   Zheng, Xiangxiong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

IL 33; lupus prone mice; myeloid derived suppressor cells; systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C3; CREATININE; CYTOKINE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 33 ANTIBODY; INTERLEUKIN 6; UNCLASSIFIED DRUG; ANTIBODY; ANTIGEN ANTIBODY COMPLEX; ANTINUCLEAR ANTIBODY; IL1B PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-33, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; FEMALE; HUMAN; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PROTEINURIA; REGULATORY T LYMPHOCYTE; SLEDAI; SUPPRESSOR CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BONE MARROW CELL; DISEASE MODEL; IMMUNE COMPLEX DISEASES; IMMUNOLOGY; INFLAMMATION; INJURIES; KIDNEY; LUPUS NEPHRITIS; MORTALITY;

MUS;

ANIMALS; ANTIBODIES; ANTIBODIES, ANTINUCLEAR; ANTIGEN-ANTIBODY COMPLEX; COMPLEMENT C3; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNE COMPLEX DISEASES; IMMUNOGLOBULIN G; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKINS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICE; MYELOID CELLS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84902539239     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9802-0     Document Type: Article

References (35)

1. Kurowska-Stolarska, M., A. Hueber, B. Stolarski, and I.B. McInnes. 2011. Interleukin-33: a novel mediator with a role in distinct disease pathologies. Journal of Internal Medicine 269: 29-35.
2. Lloyd, C.M. 2010. IL-33 family members and asthma-bridging innate and adaptive immune responses. Current Opinion in Immunology 22: 800-806.
3. Mirchandani, A.S., R.J. Salmond, and F.Y. Liew. 2012. Interleukin-33 and the function of innate lymphoid cells. Trends in Immunology 33: 389-396.
4. McLaren, J.E., D.R. Michael, R.C. Salter, T.G. Ashlin, C.J. Calder, A.M. Miller, et al. 2010. IL-33 reduces macrophage foam cell formation. The Journal of Immunology 185: 1222-1229.
5. Miller, A.M., D. Xu, D.L. Asquith, L. Denby, Y. Li, N. Sattar, et al. 2008. IL-33 reduces the development of atherosclerosis. The Journal of Experimental Medicine 205: 339-346. (Pubitemid 351281600)
6. Moffatt, M.F., I.G. Gut, F. Demenais, D.P. Strachan, E. Bouzigon, S. Heath, et al. 2010. A large-scale, consortium-based genomewide association study of asthma. The New England Journal of Medicine 363: 1211-1221.
7. Xu, D., H.R. Jiang, P. Kewin, Y. Li, R. Mu, A.R. Fraser, et al. 2008. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proceedings of the National Academy of Sciences of the United States of America 105: 10913-10918.
8. Talabot-Ayer, D., T. McKee, P. Gindre, S. Bas, D.L. Baeten, C. Gabay, et al. 2012.Distinct serumand synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint, Bone, Spine 79: 32-37.
9. Humrich, J.Y., H. Morbach, R. Undeutsch, P. Enghard, S. Rosenberger, O. Weigert, et al. 2010. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proceedings of the National Academy of Sciences of the United States of America 107: 204-209.
10. Trigunaite A, Khan A, Der E, Song A, Varikuti S, Jørgensen TN. Gr1(high) CD11b(+) cells suppress B cell differentiation and lupuslike disease in lupus-prone male mice. Arthritis Rheum. 2013. doi:10.1002/art.38048.
11. Gabrilovich, D.I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 9: 162-174.
12. Peranzoni, E., S. Zilio, I. Marigo, L. Dolcetti, P. Zanovello, S. Mandruzzato, et al. 2010. Myeloid-derived suppressor cell heterogeneity and subset definition. Current Opinion in Immunology 22: 238-244.
13. Ioannou, M., T. Alissafi, I. Lazaridis, G. Deraos, J. Matsoukas, A. Gravanis, et al. 2012. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. The Journal of Immunology 188: 1136-1146.
14. Fujii, W., E. Ashihara, H. Hirai, H. Nagahara, N. Kajitani, K. Fujioka, et al. 2013. Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. The Journal of Immunology 191: 1073-1081.
15. Tsokos, G.C. 2011. Systemic lupus erythematosus. The New England Journal of Medicine 365: 2110-2121.
16. Kim, Y.H., T.Y. Yang, C.S. Park, S.H. Ahn, B.K. Son, J.H. Kim, et al. 2012. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 67: 183-190.
17. Sekine, H., K.L. Graham, S. Zhao, M.K. Elliott, P. Ruiz, P.J. Utz, et al. 2006. Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus. The Journal of Immunology 177: 7423-7434. (Pubitemid 44715113)
18. Wellmann, U., M. Letz, A. Schneider, K. Amann, and T.H. Winkler. 2001. An Ig μ-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB x NZW)F1 mice. International Immunology 13: 1461-1469. (Pubitemid 33133875)
19. Lateef, A., and M. Petri. 2012. Unmetmedical needs in systemic lupus erythematosus. Arthritis Research and Therapy 14(Suppl 4): S4.
20. Yang, Z., Y. Liang, W. Xi, C. Li, and R. Zhong. 2011. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clinical and Experimental Medicine 11: 75-80.
21. Mok, M.Y., F.P. Huang, W.K. Ip, Y. Lo, F.Y. Wong, E.Y. Chan, et al. 2010. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 49: 520-527.
22. Oboki, K., T. Ohno, N. Kajiwara, K. Arae, H. Morita, A. Ishii, et al. 2010. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proceedings of the National Academy of Sciences of the United States of America 107: 18581-18586.
23. Hong, Y.S., S.J. Moon, Y.B. Joo, C.H. Jeon, M.L. Cho, J.H. Ju, et al. 2011. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. Journal of Korean Medical Science 26: 1132-1139.
24. Kunisch, E., S. Chakilam, M. Gandesiri, and R.W. Kinne. 2012. IL-33 regulates TNF-α dependent effects in synovial fibroblasts. International Journal of Molecular Medicine 29: 530-540.
25. Yin, B., G. Ma, C.Y. Yen, Z. Zhou, G.X. Wang, C.M. Divino, et al. 2010. Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. The Journal of Immunology 185: 5828-5834.
26. Wolf, D., K. Hochegger, A.M. Wolf, H.F. Rumpold, G. Gastl, H. Tilg, et al. 2005. CD4+ CD25+ regulatory Tcells inhibit experimental antiglomerular basement membrane glomerulonephritis in mice. Journal of the American Society of Nephrology 16: 1360-1370. (Pubitemid 41716520)
27. Weigert, O., C. von Spee, R. Undeutsch, L. Kloke, J.Y. Humrich, and G. Riemekasten. 2013. CD4 + Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice. Arthritis Research and Therapy 15: R35.
28. Shin, M.S., N. Lee, and I. Kang. 2011. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Current Opinion in Rheumatology 23: 444-448.
29. Ambrosi, A., A. Espinosa, and M. Wahren-Herlenius. 2012. IL-17: a new actor in IFN-driven systemic autoimmune diseases. European Journal of Immunology 42: 2274-2284.
30. Ma, J., J. Yu, X. Tao, L. Cai, J. Wang, and S.G. Zheng. 2010. The imbalance between regulatory and IL-17-secreting CD4+ T cells in lupus patients. Clinical Rheumatology 29: 1251-1258.
31. Mengya, Z., M. Hanyou, L. Dong, L. Xiaohong, and Z. Lihua. 2013. Th17/Treg imbalance induced by increased incidence of atherosclerosis in patients with systemic lupus erythematosus (SLE). Clinical Rheumatology 32: 1045-1052.
32. Zhao, J., H. Wang, C. Dai, H. Wang, H. Zhang, Y. Huang, et al. 2013. P2X7 blockade attenuates lupus nephritis by inhibiting NLRP3/ASC/caspase-1 activation. Arthritis and Rheumatism 65: 3176-3185.
33. + regulatory T-cell responses in mice. Molecular Medicine 18: 753-761.
34. Jiang, H.R., M. Milovanović, D. Allan, W. Niedbala, A.G. Besnard, S.Y. Fukada, et al. 2012. IL-33 attenuates EAE by suppressing IL-17 and IFN-α production and inducing alternatively activated macrophages. European Journal of Immunology 42: 1804-1814.
35. Mu, R., H.Q. Huang, Y.H. Li, C. Li, H. Ye, and Z.G. Li. 2010. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. The Journal of Rheumatology 37: 2006-2013.